23 May 2019
Visiongain has launched a new pharma report Biobanking Market Forecasts 2019-2029 : Research, Therapeutic, Human Tissue, Stem Cells, Commercial Sector, Public Sector, Umbilical Cord Banking, Adult Stem Cell Banking, Consumables, Equipment, Services, Freezers & Refrigerators, Cryogenic Storage Systems, Incubators & Centrifuges, Thawing Equipment, Temperature Control Systems, Alarms & Monitoring Systems.
The demand for resources stored in biobanks is growing worldwide. The value of human biologic specimens for research is increasing. Biologic specimens housed in biobanks are being increasingly used in epidemiological investigations into various diseases. The overall biobanking market is estimated to grow at a CAGR of 6.6% in the first half of the forecast period. The use of biobanks for therapeutic applications is also increasing, such as in the stem cell banking sector. Efforts are being made to establish biobanking networks, harmonising biobanking practices and condensing that industry.
The lead analyst of the report commented "Biobanking infrastructure is improving at a global level with the establishment of large-scale national biobanks, population biobank projects, virtual biobanks and networking at national and international level. The result of this improving infrastructure is the condensing of the biobanking industry and expanding access to samples. This will drive growth during the forecast period.
For innovative research to drive the biobanking industry, the biobanking industry must recognise the importance of standardisation and harmonisation. Biobanks must also shift towards integrated systems for higher efficiency. Integrating hardware, software, consumables and automation can allow a biobank to function more smoothly and quickly."
Leading companies featured in the report include Asterand Bioscience (Stemgent), Biogenea Pharmaceuticals, Biopta (ReproCELL), BioServe, Caladrius Biosciences, China Cord Blood Corp, Cord Blood America, Danaher, LifebankUSA, Qiagen, StemLife, Thermo Fisher Scientific, Inc., Tissue Solutions, ViaCord and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.